| Literature DB >> 28477316 |
Anne-Claire Brehin1,2, Sophie Patrier-Sallebert1, Gaëlle Bougeard2, Gwendoline Side-Pfennig1, Francisco Llamas Gutierrez3, Aude Lamy1, Elodie Colasse1, Christine Kandel-Aznar4, Capucine Delnatte5, Eric Vuillemin6, Sophie Sadot-Lebouvier7, Sylvie Odent8, Jean-Christophe Sabourin1, François Golfier9, Thierry Frebourg10.
Abstract
Choriocarcinoma is a highly malignant neoplasm resulting from the malignant transformation of proliferating trophoblastic cells and the molecular mechanisms leading to this transformation remain to be characterized. We report here the first case of a female germline TP53 mutation carrier who developed, as a first tumour, a lung choriocarcinoma, 6 months after a normal delivery. Molecular analyses established the gestational origin of the choriocarcinoma and showed, within the tumour, the presence of the germline mutant TP53 allele and loss of the wild-type allele. Resistance to methotrexate chemotherapy led to perform a surgical resection of the tumour. In agreement with the permissive role of TP53 mutations to oncogenic events, this report strongly suggests that TP53 mutations may promote malignant transformation of proliferating trophoblastic cells. Therefore, female TP53 mutation carriers may have an increased risk of developing gestational choriocarcinoma and might benefit from β-hCG level monitoring after pregnancy.Entities:
Keywords: Choriocarcinoma; Gestational choriocarcinoma; Gestational trophoblastic disease; Li-Fraumeni syndrome; TP53
Mesh:
Substances:
Year: 2018 PMID: 28477316 DOI: 10.1007/s10689-017-9996-7
Source DB: PubMed Journal: Fam Cancer ISSN: 1389-9600 Impact factor: 2.375